James C Yao

Publications398
h-index73
Citations26,217
Highly Influential Citations1,187
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Kulke
  • 371 Publications • 19,011 Citations
  • M. Pavel
  • 324 Publications • 14,531 Citations
  • J. Strosberg
  • 342 Publications • 12,356 Citations
  • R. Jensen
  • 829 Publications • 38,384 Citations
  • Publications
  • Influence
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
TLDR
Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors, suggesting that NETs are more prevalent than previously reported.
View on PubMed
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
TLDR
Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
View on Wolters Kluwer
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
TLDR
Survival for all NETs has improved over time, especially for distant-stage gastrointestinal NETs and pancreatic NETs in particular, reflecting improvement in therapies.
View on Wolters Kluwer
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
TLDR
RAD001 at 5 or 10 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity, and confirmatory studies are ongoing.
View on PubMed
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
TLDR
Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy.
View on PubMed
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
View on Elsevier
Everolimus for advanced pancreatic neuroendocrine tumors.
TLDR
Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events.
View on PubMed
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
View on Elsevier
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
TLDR
Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS, and the volume of metastases in the liver is the most important predictor of outcome.
View on PubMed
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
TLDR
An overview of well-differentiated neuroendocrine tumors of the stomach and pancreas is provided and consensus guidelines for the treatment of patients with these malignancies are described.
View on PubMed
...
...